ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

CDXC ChromaDex Corporation

3,80
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:04
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
ChromaDex Corporation CDXC NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 3,80 10:00:04
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,80
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202414:32BWChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR),..
25.4.202414:34BWChromaDex Announces Nationwide Launch of Tru Niagen® at The..
24.4.202414:34BWChromaDex to Report First Quarter 2024 Financial Results on..
23.4.202414:32BWChromaDex Announces Inaugural Major Grocery Debut of Tru..
26.3.202413:32BWChromaDex Announces Tru Niagen® is Now Third-Party Verified..
06.3.202422:04BWChromaDex Corporation Reports Fourth Quarter and Fiscal Year..
06.3.202422:02EDGAR2Form 8-K - Current report
06.3.202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
24.2.202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.2.202402:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202414:32BWChromaDex to Report Fourth Quarter 2023 Financial Results on..
05.2.202414:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
26.1.202422:08BWChromaDex to Present at the Lytham Partners 2024 Investor..
20.12.202315:04BWChromaDex Supports the US Military with its Industry Leading..
13.12.202322:00EDGAR2Form 8-K - Current report
12.12.202316:30PRNUSNeurohacker Collective and ChromaDex Partner to Optimize..
04.12.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.11.202314:34BWA Milestone Phase I Randomized, Double-Blind Clinical Trial..
15.11.202314:32BWNewly Published Phase II Clinical Study Demonstrates that..
09.11.202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
08.11.202322:02EDGAR2Form 8-K - Current report
08.11.202322:02BWChromaDex Corporation Reports Third Quarter 2023 Financial..
08.11.202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202313:34BWChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg..
31.10.202313:34BWChromaDex to Report Third Quarter 2023 Financial Results on..
26.10.202314:32BWChromaDex and Zesty Paws® Crack the Code on Cellular Health..
02.10.202314:32BWA Milestone Clinical Study Reveals that Elevating..
07.9.202312:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.9.202312:20EDGAR2Form SC 13D/A - General statement of acquisition of..
24.8.202314:32BWPreclinical Study Builds on Growing Body of Evidence..
16.8.202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.8.202322:02EDGAR2Form 8-K - Current report
09.8.202322:02BWChromaDex Corporation Reports Second Quarter 2023 Financial..
09.8.202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202314:34BWChromaDex Launches Tru Niagen® with iHerb, the World’s..
07.8.202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
02.8.202314:02BWChromaDex to Report Second Quarter 2023 Financial Results on..
18.7.202314:32BWFindings from Published Abstracts Showcase the Importance of..
06.7.202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.7.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
16.6.202314:32BWChromaDex, a Global Authority on Nicotinamide Adenine..
30.5.202314:34BWChromaDex to Participate in the LD Micro Invitational XIII
11.5.202314:34BWChromaDex to Present at the Lytham Partners Spring 2023..
10.5.202322:02BWChromaDex Corporation Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock